As Alzheimer’s trials move earlier in the disease continuum, measuring treatment benefit becomes increasingly complex. Hear from Ed Bartolic, who joined our partners at Clinical ink on bringing the science and execution together: buff.ly/xe2Y3fb
Cogstate
@Cogstate
Simplifying brain health measurement.
262 Following 696 Followers 766 Posts
Latest posts 5
Digital PACC assessments developed and validated by Cogstate reduce burden on raters, while also reducing participant and site burden and supporting valid, reliable measurement across diverse populations.
Explore these innovations in our whitepaper. buff.ly/FuWEi4u
Explore these innovations in our whitepaper. buff.ly/FuWEi4u
Cogstate researchers and collaborators will share work at #CTAD26 spanning AD biomarkers and cognitive change, early detection, digital measures and assessment performance. Explore our presentations, and connect with us in Boston: buff.ly/iaICdvM
CTAD 2026 brings important conversations on the future of Alzheimer’s disease research, from new trial readouts to advances in digital measures, biomarkers and diagnostics. Connect with us in Boston: buff.ly/iaICdvM
New data from Cogstate scientist Karra Harrington shows strong concordance between Cogstate’s self-administered LILA app and telehealth-administered assessments—supporting a more flexible, accessible approach to cognitive screening. Review the poster: buff.ly/YWuxbwT